Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

Institut de Cancérologie de Lorraine

Status: Enrolling

Conditions: Melanoma

Treatments: Procedure: Personalized Circulating DNA follow-up

Study type: Interventional

Funder types: Other

Identifiers

NCT04866680

2022-A01904-39

Details and patient eligibility

About

PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.

Enrollment: 165 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• locally advanced, operable melanoma
• treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.

Exclusion criteria

• second cancer
• woman who is pregnant, likely to be pregnant or breastfeeding

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

165 participants in 1 patient group

Personalized Circulating DNA follow-up

Experimental group

Description:

FFPE tissue sample + blood sample (20ml)

Treatment:

Procedure: Personalized Circulating DNA follow-up